Histology-Stratified Tumor Control and Patient Survival After Stereotactic Radiosurgery for Pineal Region Tumors: A Report From the International Gamma Knife Research Foundation
Language English Country United States Media print-electronic
Document type Journal Article, Multicenter Study
PubMed
28751141
DOI
10.1016/j.wneu.2017.07.097
PII: S1878-8750(17)31197-X
Knihovny.cz E-resources
- Keywords
- Gamma knife radiosurgery, Pineal region tumors, Survival, Tumor control,
- MeSH
- Child MeSH
- Adult MeSH
- Pineal Gland pathology surgery MeSH
- Internationality * MeSH
- Cohort Studies MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local mortality pathology surgery MeSH
- Survival Rate trends MeSH
- Adolescent MeSH
- Young Adult MeSH
- Brain Neoplasms mortality pathology surgery MeSH
- Follow-Up Studies MeSH
- Pinealoma mortality pathology surgery MeSH
- Child, Preschool MeSH
- Radiosurgery mortality trends MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Research Report MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
BACKGROUND: Pineal region tumors represent a rare and histologically diverse group of lesions. Few studies are available to guide management and the outcomes after stereotactic radiosurgery (SRS). METHODS: Patients who underwent SRS for a pineal region tumor and for whom at least 6 months of imaging follow-up was available were retrospectively assessed in 5 centers. Data were collected from the medical record and histology level analyses were performed, including actuarial tumor control and survival analyses. RESULTS: A total of 70 patients were treated between 1989 and 2014 with a median follow-up of 47 months. Diagnoses were pineocytoma (37%), pineoblastoma (19%), pineal parenchymal tumor of intermediate differentiation (10%), papillary tumor of the pineal region (9%), germinoma (7%), teratoma (3%), embryonal carcinoma (1%), and unknown (14%). Median prescription dose was 15 Gy at the 50% isodose line. Actuarial local control and survival rates were 81% and 76% at 20 years for pineocytoma, 50% and 56% at 5 years for pineal parenchymal tumor of intermediate differentiation, 27% and 48% at 5 years for pineoblastoma, 33% and 100% at 5 years for papillary tumor of the pineal region, 80% and 80% at 20 years for germinoma, and 61% and 67% at 5 years for tumors of unknown histology. New focal neurological deficit, Parinaud syndrome, and hydrocephalus occurred in 9%, 7%, and 3% of cases, respectively. CONCLUSIONS: SRS is a safe modality for the management of pineal region tumors. Its specific role is highly dependent on tumor histology. As such, all efforts should be made to obtain a reliable histologic diagnosis.
Department of Neurological Surgery University of Virginia Charlottesville Virginia USA
Na Homolce Hospital Prague Czech Republic
Taipei Veterans General Hospital Neurological Institute Taipei Taiwan
References provided by Crossref.org